INOVIO PHARMACEUTICALS, INC.INOEarnings & Financial Report
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.
INO Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-21.2M
Net Profit
$-45.5M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.87
INOVIO PHARMACEUTICALS, INC. Q3 2025 Financial Summary
INOVIO PHARMACEUTICALS, INC. reported revenue of $0 for Q3 2025, with a net profit of $-45.5M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-45.5M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
INOVIO PHARMACEUTICALS, INC. Annual Revenue by Year
INOVIO PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $217.8K).
| Year | Annual Revenue |
|---|---|
| 2024 | $217.8K |
| 2023 | $832.0K |
| 2022 | $10.3M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $102650 | $0 | $100762 | $0 | $116994 | $65343 | $0 | $0 |
| YoY Growth | -17.7% | N/A | -55.4% | N/A | 14.0% | N/A | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $171.0M | $129.1M | $133.8M | $107.1M | $113.2M | $87.3M | $68.2M | $69.4M |
| Liabilities | $53.6M | $34.7M | $37.1M | $33.5M | $44.7M | $36.0M | $39.7M | $77.1M |
| Equity | $117.3M | $94.4M | $96.7M | $73.5M | $68.5M | $51.3M | $28.5M | $-7.7M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-26.3M | $-28.8M | $-28.2M | $-27.4M | $-19.7M | $-26.9M | $-20.8M | $-21.6M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M